ライフサイエンスコーパス: zeaxanthin

1 ; P = .61 for lutein/zeaxanthin vs no lutein/zeaxanthin).

2 ay can provide a high enough level (2 mg) of zeaxanthin.

3 e was rich in antheraxanthin, capsanthin and zeaxanthin.

4 est degradation rates followed by lutein and zeaxanthin.

5 well as the tightly regulated production of zeaxanthin.

6 to be partially phosphorylated and contained zeaxanthin.

7 ls showing continuous exposure to lutein and zeaxanthin.

8 r adjusting for dietary intake of lutein and zeaxanthin.

9 pha-carotene, beta-cryptoxanthin, and lutein/zeaxanthin.

10 ellow, blue-absorbing carotenoids lutein and zeaxanthin.

11 aggregate of the carotenoid all-trans 3R,3'R-zeaxanthin.

12 and antheraxanthin are deepoxidized to form zeaxanthin.

13 presence of the xanthophyll cycle carotenoid zeaxanthin.

14 rabidopsis thaliana npq1 mutant, which lacks zeaxanthin.

15 erol (P = 0.0025) but was unrelated to serum zeaxanthin.

16 ed from 0.71 for lycopene to 0.95 for lutein-zeaxanthin.

17 id not change the serum levels of lutein and zeaxanthin.

18 d a carotenoid generated by the retina, meso-zeaxanthin.

19 is affected by both DeltapH and the level of zeaxanthin.

20 e-epoxidation of LHCII-bound violaxanthin to zeaxanthin.

21 ne, beta-carotene, lycopene, and lutein plus zeaxanthin.

22 es, including the unique macula pigment meso-zeaxanthin.

23 otene (20%), with minor levels of lutein and zeaxanthin.

24 otene (0.84; 95% CI: 0.77, 0.93), and lutein/zeaxanthin (0.87; 95% CI: 0.79, 0.95).

25 tene, 0.28; beta-cryptoxanthin, 0.35; lutein/zeaxanthin, 0.28; lycopene, 0.15; folate, 0.26; alpha-to

26 arotene, 0.53; beta-carotene, 0.39; lutein + zeaxanthin, 0.46; lycopene, 0.32; and alpha-tocopherol,

27 [98.7% CI, 0.76-1.07]; P = .12 for lutein + zeaxanthin; 0.97 [98.7% CI, 0.82-1.16]; P = .70 for DHA

28 otene (1.04; 95% CI: 0.98, 1.10), and lutein/zeaxanthin (1.00; 95% CI: 0.93, 1.07).

29 1 of the following 4 groups: placebo; lutein/zeaxanthin, 10 mg/2 mg; omega-3 long-chain polyunsaturat

30 capsule containing 10 mg of lutein, 1 mg of zeaxanthin, 100 mg of docosahexaenoic acid, and 30 mg of

31 e randomly assigned to daily placebo; lutein/zeaxanthin, 10mg/2mg; omega-3 long-chain polyunsaturated

32 acids (LCPUFAs) (1 g) and/or lutein (10 mg)/zeaxanthin (2 mg) vs placebo were tested in a factorial

33 were randomized to receive lutein (10 mg) + zeaxanthin (2 mg), DHA (350 mg) + EPA (650 mg), lutein +

34 .86+/-1.76 mug/g) while mais has the highest zeaxanthin (269.1+/-11.8 mug/g).

35 % (468 eyes [399 participants]) for lutein + zeaxanthin, 31% (507 eyes [416 participants]) for DHA +

36 id contents (beta carotene, 14.25 mug/100 g; zeaxanthin, 35.21 mug/100 g; lutein 174.59 mug/100 g) as

37 ing of phycobilisomes rods and regulation of zeaxanthin abundance.

38 Studies in BCO2-knockout mice revealed that zeaxanthin accumulates in the inner mitochondrial membra

39 f zeaxanthin to the L2 domain, implying that zeaxanthin acts as an allosteric effector of charge tran

40 , which is necessary for the accumulation of zeaxanthin, affects the excited-state chlorophyll relaxa

41 e assumption of weak exciton-coupling in the zeaxanthin aggregate.

42 idual carotenoid contents, including lutein, zeaxanthin , alpha-carotene, beta-carotene, and lycopene

43 Sastra showed the highest content of zeaxanthin among the fruit investigated.

44 oxide, together with (all-E)-lutein, (all-E)-zeaxanthin and (all-E)-beta-carotene were found at high

45 the relations between intakes of lutein and zeaxanthin and age-related macular degeneration (AMD) ha

46 as characterized by high levels of all-trans-zeaxanthin and all-trans-beta-carotene (755 and 332mug/g

47 or xanthophylls (all-trans-lutein, all-trans-zeaxanthin and all-trans-beta-cryptoxanthin).

48 immon powder for all-trans-lutein, all-trans-zeaxanthin and all-trans-beta-cryptoxanthin, respectivel

49 est, including the structural isomers lutein/zeaxanthin and alpha-/beta-carotene.

50 plasma xanthophyll concentrations (lutein + zeaxanthin and beta-cryptoxanthin) and hydrocarbon carot

51 n were the free hydroxy xanthophylls lutein, zeaxanthin and beta-cryptoxanthin.

52 is-violaxanthin, lutein, beta-cryptoxanthin, zeaxanthin and cis-antheraxanthin) were investigated at

53 Pistachios were rich in lutein/zeaxanthin and contained highest beta-carotene levels am

54 [98.7% CI, 0.75-1.06]; P = .10 for lutein + zeaxanthin and DHA + EPA).

55 2 mg), DHA (350 mg) + EPA (650 mg), lutein + zeaxanthin and DHA + EPA, or placebo.

56 % (472 eyes [387 participants]) for lutein + zeaxanthin and DHA + EPA.

57 plants have a partially restored qE but lack zeaxanthin and have low levels of violaxanthin, antherax

58 hin monomeric LHC proteins depending on both zeaxanthin and lutein and on the formation of a radical

59 arotene and the non-provitamin A carotenoids zeaxanthin and lutein, and is inactive with all-trans-ly

60 in the npq1 lor1 double mutant, which lacks zeaxanthin and lutein.

61 ntensity on the presence and accumulation of zeaxanthin and lutein.

62 Year 0 lutein/zeaxanthin and lycopene were not associated with maximum

63 n mice and primates of a binding protein for zeaxanthin and meso-zeaxanthin, the pi isoform of glutat

64 e protective carotenoid pigments, especially zeaxanthin and myxoxanthophyll, were up-regulated in the

65 nge peppers were the best sources of lutein, zeaxanthin and neoxanthin.

66 tial interactions between LCPUFAs and lutein/zeaxanthin and none were found to be significant.

67 Increased dietary intake of lutein/zeaxanthin and omega-long-chain polyunsaturated fatty ac

68 eration of a strain constitutively producing zeaxanthin and showing improved photosynthetic productiv

69 beta-carotene and two dicyclic xanthophylls, zeaxanthin and synechoxanthin.

70 ends on the nutritional uptake of lutein and zeaxanthin and that it is inversely associated with the

71 healthy diet in regard to B-vitamins, lutein/zeaxanthin and tocopherols.

72 n, while an opposite effect was observed for zeaxanthin and violaxanthin.

73 ding protein of photosystem II) or pigments (zeaxanthin and/or lutein) required for photoprotective t

74 ndomized controlled clinical trial of lutein/zeaxanthin and/or omega-3 fatty acids, the Age-Related E

75 luate the efficacy and safety of lutein plus zeaxanthin and/or omega-3 long-chain polyunsaturated aci

76 -based macular xanthophylls (MXs; lutein and zeaxanthin) and the lutein metabolite meso-zeaxanthin ar

77 We did not detect any activity with lutein, zeaxanthin, and 9-cis-beta-carotene.

78 posed of two dietary carotenoids, lutein and zeaxanthin, and a carotenoid generated by the retina, me

79 content on a chlorophyll basis, particularly zeaxanthin, and a major down-regulation of light absorpt

80 the contents of free amino acid, lutein and zeaxanthin, and increased the MDA content in eggs.

81 nthin, alpha-carotene, beta-carotene, lutein/zeaxanthin, and lycopene) and the evolution of lung func

82 The present study evaluated serum lutein, zeaxanthin, and macular pigment optical density (MPOD) r

83 ng affinities between human BCO2 and lutein, zeaxanthin, and meso-zeaxanthin are 10- to 40-fold weake

84 The prevalence of lutein, zeaxanthin, and meso-zeaxanthin in supplements is increa

85 nce on the putative role of the MXs (lutein, zeaxanthin, and meso-zeaxanthin) in AMD and report findi

86 ounts of the xanthophyll carotenoids lutein, zeaxanthin, and meso-zeaxanthin, but the underlying bioc

87 nt containing a fixed combination of lutein, zeaxanthin, and omega-3 LC-PUFAs during 12 months signif

88 Nutritional uptake of lutein, zeaxanthin, and omega-3 polyunsaturated fatty acids may

89 LHCs), the de-epoxidation of violaxanthin to zeaxanthin, and the photosystem II subunit S (PsbS) work

90 convolution of the relative contributions of zeaxanthin- and lutein-dependent NPQ.

91 Mathematical models of the response of zeaxanthin- and lutein-dependent reversible NPQ were con

92 lacks VDE and cannot convert violaxanthin to zeaxanthin; and npq1 npq4, which lacks both VDE and PsbS

93 Five carotenoids, namely lutein, zeaxanthin, antheraxanthin, alpha- and beta-carotene, we

94 Dietary intake of lutein and zeaxanthin appears to be advantageous for protecting hum

95 human BCO2 and lutein, zeaxanthin, and meso-zeaxanthin are 10- to 40-fold weaker than those for mous

96 rs and former smokers and because lutein and zeaxanthin are important components in the retina.

97 tional changes under the presence of DeltapH/zeaxanthin are related to the PsbS role in the current n

98 d zeaxanthin) and the lutein metabolite meso-zeaxanthin are the major constituents of macular pigment

99 Among the carotenoids, lutein and zeaxanthin are the only two that cross the blood-retina

100 nd with log(e) serum lutein and log(e) serum zeaxanthin as independent variables adjusting for age, s

101 Adjusting for dietary lutein and zeaxanthin attenuated, and therefore partially explained

102 Thiamine, riboflavin, pyridoxine, lutein, zeaxanthin, beta-carotene and alpha-/gamma-tocopherol we

103 Levels of lutein, zeaxanthin, beta-cryptoxanthin and beta-carotene in hexa

104 surface responses were generated for lutein, zeaxanthin, beta-cryptoxanthin and beta-carotene in kaki

105 ds in humans (phytoene, phytofluene, lutein, zeaxanthin, beta-cryptoxanthin, alpha-carotene, beta-car

106 a-carotene, beta-carotene, lycopene, lutein, zeaxanthin, beta-cryptoxanthin, retinol, alpha-tocophero

107 ncludes variants in or near genes related to zeaxanthin binding in the macula (GSTP1), carotenoid cle

108 ric antenna complexes of Photosystem II upon zeaxanthin binding; however, the amplitude of carotenoid

109 which has previously been identified as the zeaxanthin-binding protein of the primate macula.

110 n resulted in significant inhibition of meso-zeaxanthin biosynthesis during chicken eye development.

111 DNA consisting of three genes), a functional zeaxanthin biosynthesis pathway (approximately 11 kb DNA

112 functional combined D-xylose utilization and zeaxanthin biosynthesis pathway (approximately 19 kb con

113 se of the system, we assembled the five-gene zeaxanthin biosynthetic pathway in a single step and sho

114 ne, beta-cryptoxanthin, lycopene, and lutein-zeaxanthin, blood lipids, Hb A(1c), and CRP were availab

115 vitamin C, beta-cryptoxanthin, and lutein + zeaxanthin but lower folate and vitamin D concentrations

116 yll carotenoids lutein, zeaxanthin, and meso-zeaxanthin, but the underlying biochemical mechanisms fo

117 itro oxidation of beta-carotene, lutein, and zeaxanthin by (1)O(2) generated various aldehydes and en

118 ble for the transformation of lutein to meso-zeaxanthin by a double-bond shift mechanism, but its ide

119 c flicker photometry, serum lutein and serum zeaxanthin by high performance liquid chromatography, an

120 into consideration, the idea that lutein and zeaxanthin can influence cognitive function in older adu

121 ation of individual carotenoids such lutein, zeaxanthin, canthaxanthin, ss-carotene and beta-apocarot

122 st that increased dietary intake of lutein + zeaxanthin (carotenoids), omega-3 long-chain polyunsatur

123 In contrast, zeaxanthin cleavage dioxygenase (ZCD), an enzyme previou

124 monstrated that only mouse BCO2 is an active zeaxanthin cleavage enzyme.

125 as significantly related to serum lutein and zeaxanthin combined (r = 0.31, P = 0.002), GD (r = 0.24,

126 ation-based study in centenarians found that zeaxanthin concentrations in brain tissue were significa

127 a relation between cognition and lutein and zeaxanthin concentrations in the brain tissue of deceden

128 change in provitamin A carotenoid and lutein/zeaxanthin concentrations was associated with a slower d

129 Differences in lutein and zeaxanthin concentrations were small.

130 -12, folate, beta-cryptoxanthin, lutein, and zeaxanthin concentrations.

131 Arabidopsis thaliana mutant that accumulates zeaxanthin constitutively, have reported that this xanth

132 nt with the high rate of habitual lutein and zeaxanthin consumption in Utah AREDS2 subjects prior to

133 This type of quenching, together with high zeaxanthin content, appears to underlie photoprotection

134 Lutein and zeaxanthin contents were lower in non-corn cereal endosp

135 e of lung cancer in former smokers, lutein + zeaxanthin could be an appropriate carotenoid substitute

136 REDS2 and other studies suggests that lutein/zeaxanthin could be more appropriate than beta carotene

137 REDS2 and other studies suggests that lutein/zeaxanthin could be more appropriate than beta-carotene

138 cherichia coli strains engineered to produce zeaxanthin demonstrated that only mouse BCO2 is an activ

139 ential spectroscopy in vivo, we identified a zeaxanthin-dependent optical signal characterized by a r

140 enetically dissected different components of zeaxanthin-dependent photoprotection.

141 relative to D3, combined with an increase in zeaxanthin-dependent quenching (qZ) relative to D4.

142 component of quenching was less dependent on zeaxanthin, despite the near-complete violaxanthin to ze

143 Addition of lutein + zeaxanthin, DHA + EPA, or both to the AREDS formulation

144 e main fraction among berry varieties having zeaxanthin di-palmitate as major compound, while leaves

145 ed, including beta-carotene and 10 different zeaxanthin-di-esters.

146 a-3 LCPUFA to oral supplementation of lutein/zeaxanthin did not change the serum levels of lutein and

147 Increases in serum levels of lutein/zeaxanthin did not differ by omega-3 LCPUFA treatment (P

148 as not modified after 6 months of lutein and zeaxanthin dietary supplementation despite plasma levels

149 ) for those randomized to not receive lutein/zeaxanthin (difference in yearly change, 0.03 [99% CI, -

150 antioxidant activity and contents of rutin, zeaxanthin dipalmitate and 2-O-beta-d-glucopyranosyl-l-a

151 ied by an accumulation of up to 36mg/100g FW zeaxanthin dipalmitate and further minor xanthophyll est

152 In the case of zeaxanthin dipalmitate the retention level was around 40

153 rotenoid found in wheat and tritordeum while zeaxanthin dominated in barley.

154 1 (high pigment1 [hp1]), Deetiolated1 (hp2), Zeaxanthin Epoxidase (hp3), and Intense pigment (Ip; gen

155 Since zeaxanthin epoxidase (ZEP) depletes the carotenoid pool

156 ZEAXANTHIN EPOXIDASE (ZEP) was the major contributor to

157 ified at different physical positions in the zeaxanthin epoxidase gene (ABSCISIC ACID DEFICIENT 1/ZEA

158 r flesh colour beta-carotene hydroxylase and zeaxanthin epoxidase were ranked first and forty-fourth

159 suggest that loss of function of DDB1, DET1, Zeaxanthin Epoxidase, and Ip up-regulates CHRC levels.

160 in epoxidase gene (ABSCISIC ACID DEFICIENT 1/ZEAXANTHIN EPOXIDASE, or ABA1/ZEP) in TG01 and TG10.

161 n, despite the near-complete violaxanthin to zeaxanthin exchange in LHC proteins.

162 tio comparing lutein/zeaxanthin vs no lutein/zeaxanthin for progression to cataract surgery was 0.68

163 anthin to 0.89 for alpha-carotene and lutein-zeaxanthin; for serum concentrations, the RRs ranged fro

164 es not require a transthylakoid pH gradient, zeaxanthin formation, or the phosphorylation of light-ha

165 eta-carotene, beta-cryptoxanthin, and lutein-zeaxanthin from food (P < 0.05).

166 eta-carotene, beta-cryptoxanthin, and lutein-zeaxanthin from food, or a diet high in their food sourc

167 eta-carotene, beta-cryptoxanthin, and lutein-zeaxanthin from food: 0.27 (0.14, 0.55).

168 e, beta-cryptoxanthin, lycopene, lutein, and zeaxanthin from foods and supplements.

169 cell culture leads to the production of meso-zeaxanthin from lutein.

170 enhanced liberation and bioaccessibility of zeaxanthin from these tubular aggregates in goji berries

171 ression to cataract surgery in the no lutein/zeaxanthin group was 24%.

172 s (vde lhcsr KO and vde psbs KO) showed that zeaxanthin had a major influence on LHCSR-dependent NPQ,

173 oral supplementation with LCPUFAs or lutein/zeaxanthin had no statistically significant effect on co

174 Daily supplementation with lutein/zeaxanthin had no statistically significant overall effe

175 y acids, and macular xanthophylls lutein and zeaxanthin have been associated with a lower risk of pre

176 antioxidants such as vitamin C, lutein, and zeaxanthin have been associated with lower incidence and

177 otenoids, particularly lycopene, lutein, and zeaxanthin, have been found to have important biological

178 he signal implies an increased efficiency of zeaxanthin in controlling chlorophyll triplet formation.

179 TCC, lutein and zeaxanthin in germ fractions were higher in non-corn cer

180 Lutein and zeaxanthin in macula from nonhuman primates were found t

181 ne, beta-cryptoxanthin, lutein, lycopene and zeaxanthin in minimally processed fresh food products, w

182 kale were stable (except alpha-carotene and zeaxanthin in peach) for 13, 9.7, 5.7, 2.5 and 7.5months

183 MP can be used as a biomarker of lutein and zeaxanthin in primate brain tissue.

184 in Arabidopsis thaliana The possible role of zeaxanthin in PSI photoprotection is discussed.

185 the higher amount of lutein substitutes for zeaxanthin in qE, implying a direct role in qE, as well

186 e prevalence of lutein, zeaxanthin, and meso-zeaxanthin in supplements is increasing.

187 2) assessed the value of substituting lutein/zeaxanthin in the AREDS formulation because of the demon

188 ut the physiology and function of lutein and zeaxanthin in the developing eye.

189 f the macular pigment carotenoids lutein and zeaxanthin in the human retina occurs early in life.

190 lex: (1) the accumulation of photoprotective zeaxanthin in the LHCI antenna and the PSI reaction cent

191 O2 knockout mice, unlike WT mice, accumulate zeaxanthin in their retinas.

192 nzyme responsible for the production of meso-zeaxanthin in vertebrates.

193 ole of the MXs (lutein, zeaxanthin, and meso-zeaxanthin) in AMD and report findings on AMD-associated

194 The TRL AUC(0-10h) of lutein and zeaxanthin increased 4-5-fold (P < 0.001), and the TRL A

195 However, a combination of DeltapH and zeaxanthin increases the proportion of PsbS bound to the

196 ; P = 0.0106), but not with dietary lutein + zeaxanthin intake (r = 0.13; P = 0.50).

197 nonlinear inverse association between lutein/zeaxanthin intake and neovascular AMD risk; the pooled m

198 associations were found between lutein plus zeaxanthin intake and presence at baseline or developmen

199 For early AMD, the association with lutein/zeaxanthin intake did not vary by smoking status, intake

200 a do not support a protective role of lutein/zeaxanthin intake on risk of self-reported early AMD.

201 Dietary lutein-zeaxanthin intake was associated with decreased likeliho

202 Lutein/zeaxanthin intake was not associated with the risk of se

203 alpha-Carotene, beta-carotene, and lutein/zeaxanthin intakes were inversely associated with the ri

204 the CCD family, catalyzes the conversion of zeaxanthin into crocetin-dialdehyde in Crocus.

205 abolizes nonprovitamin A carotenoids such as zeaxanthin into long-chain apo-carotenoids.

206 meso-Zeaxanthin is an ocular-specific carotenoid for which th

207 Higher intake of bioavailable lutein/zeaxanthin is associated with a long-term reduced risk o

208 We previously found that meso-zeaxanthin is produced in a developmentally regulated ma

209 nt violaxanthin is reversibly converted into zeaxanthin, is ubiquitous among green algae and plants a

210 Lutein and Zeaxanthin isomers (L/Zi) may counteract reactive oxygen

211 luate the efficacy and safety of lutein plus zeaxanthin (L+Z) and/or omega-3 long-chain polyunsaturat

212 9 eyes were analyzed (119 in the lutein plus zeaxanthin [L + Z] group and 120 in the placebo group).

213 ophylls, by characterizing the suppressor of zeaxanthin-less (szl) mutant of Arabidopsis (Arabidopsis

214 ependence of qE, we identified suppressor of zeaxanthin-less1 (szl1) as a suppressor of the Arabidops

215 The aleurone layer had zeaxanthin levels 2- to 5-fold higher than lutein among

216 Mother serum zeaxanthin levels correlated with infant MPOD (r = 0.59,

217 Infant serum zeaxanthin levels correlated with MPOD (r = 0.68, P = 0.

218 ed a 60% lutein content reduction and 40% in zeaxanthin loss, showing lutein more susceptibility to i

219 lso by assessment of tocopherols, lutein and zeaxanthin losses.

220 9 mug/g of carotenoids consisting of lutein, zeaxanthin, lycopene and beta-carotene.

221 ha- and beta-carotene, cryptoxanthin, lutein/zeaxanthin, lycopene, alpha-tocopherol, selenium, and pe

222 (alpha-carotene, beta-carotene, lutein plus zeaxanthin, lycopene, and beta-cryptoxanthin) and risk o

223 e, beta-carotene, beta-cryptoxanthin, lutein/zeaxanthin, lycopene, folate, and alpha-tocopherol in re

224 Baseline concentrations of lutein/zeaxanthin, lycopene, sum of the 3 provitamin A caroteno

225 Dietary intakes of antioxidants (lutein/zeaxanthin [LZ], beta-carotene, and vitamin C), long-cha

226 R, 1.18; 95% CI, 0.96-1.45; P = 0.12; lutein/zeaxanthin main effect HR, 1.04; 95% CI, 0.85-1.28; P =

227 ogic studies suggest that dietary lutein and zeaxanthin may be of benefit in maintaining cognitive he

228 Lutein and zeaxanthin may reduce the risk of dry, age-related macul

229 ncreases of 36% and 82% (P < 0.001) in serum zeaxanthin (n = 52) after consumption of 2 and 4 egg yol

230 f dietary supplementation containing lutein, zeaxanthin, omega-3 polyunsaturated fatty acids, and vit

231 benefit of daily supplementation with lutein/zeaxanthin on AMD progression, secondary exploratory ana

232 AREDS2 was to evaluate the effects of lutein/zeaxanthin on the subsequent need for cataract surgery.

233 o mediate crocetin formation, did not cleave zeaxanthin or 3-OH-beta-apo-8'-carotenal in the test sys

234 for extracting xanthophylls such as lutein, zeaxanthin or beta-cryptoxanthin and carotenes such as b

235 showed no significant sensitivity to low pH, zeaxanthin, or low detergent conditions.

236 ne (P = .052), folate (P = .056), and lutein/zeaxanthin (P = .077).

237 ared with a previously reported constitutive zeaxanthin pathway, our inducible pathway was shown to h

238 lementation with 10 mg of lutein and 2 mg of zeaxanthin per day can slow the rate of progression of a

239 These findings suggest that zeaxanthin played an important role in the adaptation of

240 Increased consumption of lutein-zeaxanthin predicted a lower risk of progression.

241 als are needed to determine whether maternal zeaxanthin prenatal supplementation can raise infant mac

242 is up-regulated 23-fold at the time of meso-zeaxanthin production during chicken eye development, an

243 (r = 0.36; P = 0.0142), with serum lutein + zeaxanthin (r = 0.44; P = 0.0049) and with skin caroteno

244 e transfer quenching sites in CP26 involving zeaxanthin radical cation and lutein radical cation spec

245 red at approximately 980 nm, consistent with zeaxanthin radical cation formation.

246 a lutein quencher in trimers, formation of a zeaxanthin radical cation in monomers.

247 ericans (0.11; 0.07, 0.14), and the lutein + zeaxanthin ratio was higher (0.29; 0.21, 0.38) relative

248 a plain formulation showed a 35% lutein and zeaxanthin reduction.

249 to-monomer transition, and in a violaxanthin/zeaxanthin-rich membrane, at an all-atom resolution.

250 extreme quintiles of predicted plasma lutein/zeaxanthin score, we found a risk reduction for advanced

251 ta-carotene, lutein, beta-cryptoxanthin, and zeaxanthin, showed no association with risk.

252 Our findings suggest that maternal zeaxanthin status may play a more important role than lu

253 r alternate strategies to improve lutein and zeaxanthin status.

254 at is the long-term safety profile of lutein/zeaxanthin supplementation, should other carotenoids be

255 ticipants in the target tissue of lutein and zeaxanthin supplementation: The macula.

256 dase (VDE) is the key enzyme responsible for zeaxanthin synthesis from violaxanthin under excess ligh

257 ns, plants accumulate a specific carotenoid, zeaxanthin, that was shown to increase photoprotection.

258 lowest quintile of dietary intake of lutein/zeaxanthin, the hazard ratio comparing lutein/zeaxanthin

259 y analysis of lutein/zeaxanthin vs no lutein/zeaxanthin, the hazard ratio of the development of late

260 For lutein/zeaxanthin vs no lutein/zeaxanthin, the hazard ratios for progression to catarac

261 of a binding protein for zeaxanthin and meso-zeaxanthin, the pi isoform of glutathione S-transferase

262 es of a bona fide CCD, and is able to cleave zeaxanthin, the presumed precursor of saffron apocaroten

263 -beta-ionone ring and that the conversion of zeaxanthin to crocetin dialdehyde proceeds via the C30 i

264 dy of research has linked macular lutein and zeaxanthin to reduced risk of degenerative eye disease.

265 show that the high light-induced binding of zeaxanthin to specific proteins plays a major role in en

266 formation in CP26 is dependent on binding of zeaxanthin to the L2 domain, implying that zeaxanthin ac

267 Women in the highest quartile of trans-zeaxanthin, trans -anhydro-lutein, and trans-, cis-, and

268 cal evidence that native LHCSR protein binds zeaxanthin upon excess light stress.

269 or participants randomized to receive lutein/zeaxanthin vs -0.19 (99% CI, -0.25 to -0.13) for those r

270 at baseline, the direct comparison of lutein/zeaxanthin vs beta carotene showed hazard ratios of 0.76

271 tory analyses of direct comparison of lutein/zeaxanthin vs beta carotene showed hazard ratios of 0.82

272 eaxanthin, the hazard ratio comparing lutein/zeaxanthin vs no lutein/zeaxanthin for progression to ca

273 1.03 (95% CI, 0.93-1.13; P = .61 for lutein/zeaxanthin vs no lutein/zeaxanthin).

274 In exploratory analysis of lutein/zeaxanthin vs no lutein/zeaxanthin, the hazard ratio of

275 For lutein/zeaxanthin vs no lutein/zeaxanthin, the hazard ratios fo

276 beta-cryptoxanthin and beta-carotene, while zeaxanthin was absent in all sample.

277 utein nor on charge transfer events, whereas zeaxanthin was essential.

278 and beta-carotenes, lutein, violaxanthin and zeaxanthin was found under blue 33% treatment in compari

279 ly significant increase in plasma lutein and zeaxanthin was shown in the L + Z group after 3 months a

280 ne, beta-cryptoxanthin, lycopene, and lutein/zeaxanthin were associated with a significant 40% to 50%

281 ncluding beta-carotene, lycopene, lutein and zeaxanthin were determined in three isolates of heterocy

282 y exploratory analyses suggested that lutein/zeaxanthin were helpful in reducing this risk.

283 of alpha-carotene, beta-carotene, and lutein/zeaxanthin were inversely associated with risk of ER-, b

284 ne, beta-cryptoxanthin, lycopene, and lutein/zeaxanthin were measured.

285 metric isomers of the carotenoids lutein and zeaxanthin were separated using TIMS (R > 110) for [M](+

286 Lutein and zeaxanthin were the predominant carotenoids; their level

287 Xanthophylls (lutein and zeaxanthin) were less sensitive to extrusion than carote

288 e, beta-cryptoxanthin, lycopene, lutein, and zeaxanthin) were measured by using reverse-phase HPLC, a

289 e studied the dependence of NPQ reactions on zeaxanthin, which is synthesized under light stress by v

290 n known to contain strikingly high levels of zeaxanthin, while the physical deposition form and bioac

291 otenoids, beta-carotene, lycopene and lutein+zeaxanthin with 4-y change in trochanter BMD in men (P f

292 ne, beta-cryptoxanthin, lycopene, and lutein+zeaxanthin) with BMD at the hip, spine, and radial shaft

293 Lutein and zeaxanthin within the brain might also increase temporal

294 macular pigment xanthophylls lutein (L) and zeaxanthin (Z) and n-3 fatty acids may reduce this damag

295 hin (V) conversion to antheraxanthin (A) and zeaxanthin (Z) ceased after 1 h.

296 An oral preparation containing lutein (L), zeaxanthin (Z), vitamin C, vitamin E, copper, and zinc o

297 n in response to supplemental lutein (L) and zeaxanthin (Z).

298 f violaxanthin (V) to antheraxanthin (A) and zeaxanthin (Z).

299 complex of PSII (LHC-II) and the xanthophyll zeaxanthin (Zea) into proteoliposomes, we have tested th

300 tation with omega-3 fatty acids, lutein plus zeaxanthin, zinc, or beta-carotene had no statistically